Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

S. Cora Verduyn; Bonne Biesma; Franz M. N. H. Schramel; Feike W. van der Scheer; Merel K. Langenfeld; Maria A. de Peuter; Anne-Marie C. Dingemans

doi:10.1186/1477-7525-10-108

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

S. Cora Verduyn, Bonne Biesma, Franz M. N. H. Schramel, Feike W. van der Scheer, Merel K. Langenfeld, Maria A. de Peuter, Anne-Marie C. Dingemans

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	108
Journal	Health and Quality of Life Outcomes
Volume	10
DOIs	https://doi.org/10.1186/1477-7525-10-108
Publication status	Published - 10 Sep 2012

Keywords

Advanced non-small cell lung cancer
Tyrosine kinase inhibitors
EGFR mutation
Gefitinib
Quality of life
Progression free survival

Access to Document

10.1186/1477-7525-10-108

Cite this

Verduyn, S. C., Biesma, B., Schramel, F. M. N. H., van der Scheer, F. W., Langenfeld, M. K., de Peuter, M. A., & Dingemans, A-M. C. (2012). Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Health and Quality of Life Outcomes, 10, 108. https://doi.org/10.1186/1477-7525-10-108

Verduyn, S. Cora ; Biesma, Bonne ; Schramel, Franz M. N. H. ; van der Scheer, Feike W. ; Langenfeld, Merel K. ; de Peuter, Maria A. ; Dingemans, Anne-Marie C. / Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. In: Health and Quality of Life Outcomes. 2012 ; Vol. 10. pp. 108.

@article{9f8015e89a7c4af0aa8e2b4b454c0f2a,

title = "Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands",

keywords = "Advanced non-small cell lung cancer, Tyrosine kinase inhibitors, EGFR mutation, Gefitinib, Quality of life, Progression free survival",

author = "Verduyn, {S. Cora} and Bonne Biesma and Schramel, {Franz M. N. H.} and {van der Scheer}, {Feike W.} and Langenfeld, {Merel K.} and {de Peuter}, {Maria A.} and Dingemans, {Anne-Marie C.}",

year = "2012",

month = sep,

day = "10",

doi = "10.1186/1477-7525-10-108",

language = "English",

volume = "10",

pages = "108",

journal = "Health and Quality of Life Outcomes",

issn = "1477-7525",

publisher = "BioMed Central Ltd",

}

Verduyn, SC, Biesma, B, Schramel, FMNH, van der Scheer, FW, Langenfeld, MK, de Peuter, MA & Dingemans, A-MC 2012, 'Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands', Health and Quality of Life Outcomes, vol. 10, pp. 108. https://doi.org/10.1186/1477-7525-10-108

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. / Verduyn, S. Cora; Biesma, Bonne; Schramel, Franz M. N. H.; van der Scheer, Feike W.; Langenfeld, Merel K.; de Peuter, Maria A.; Dingemans, Anne-Marie C.

In: Health and Quality of Life Outcomes, Vol. 10, 10.09.2012, p. 108.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

AU - Verduyn, S. Cora

AU - Biesma, Bonne

AU - Schramel, Franz M. N. H.

AU - van der Scheer, Feike W.

AU - Langenfeld, Merel K.

AU - de Peuter, Maria A.

AU - Dingemans, Anne-Marie C.

PY - 2012/9/10

Y1 - 2012/9/10

KW - Advanced non-small cell lung cancer

KW - Tyrosine kinase inhibitors

KW - EGFR mutation

KW - Gefitinib

KW - Quality of life

KW - Progression free survival

U2 - 10.1186/1477-7525-10-108

DO - 10.1186/1477-7525-10-108

M3 - Article

C2 - 22963131

VL - 10

SP - 108

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

SN - 1477-7525

ER -